Welcome to our dedicated page for Titan Pharmaceut news (Ticker: TTNP), a resource for investors and traders seeking the latest updates and insights on Titan Pharmaceut stock.
Titan Pharmaceuticals, Inc. (formerly Nasdaq: TTNP) has generated a series of material news events that trace its evolution from a development stage biopharmaceutical company centered on the ProNeura long-term, continuous drug delivery technology to a wholly owned subsidiary within a new holding company structure. News coverage for TTNP spans technology development, asset sales, capital raising, corporate governance, listing status, and a transformative reverse merger.
Earlier news releases describe Titan as a development stage company developing proprietary therapeutics using ProNeura, with potential applications in chronic conditions where consistent, around-the-clock blood levels of medication may benefit patients. Subsequent announcements highlight a significant asset sale to Fedson, Inc., in which Titan agreed to sell certain ProNeura assets, including its portfolio of drug addiction products (Probuphine and Nalmefene implant programs) and other early development programs based on the ProNeura platform, in exchange for upfront consideration, potential milestone payments, and royalties.
Investors following TTNP-related news will also find detailed reports on multiple private placements of convertible preferred stock, including Series AA preferred stock sold to The Sire Group Ltd. and Series B and Series C preferred stock issued to Blue Harbour Asset Management L.L.C-FZ. These transactions, described in press releases and 8-K filings, include conversion features and ownership limitations linked to Nasdaq listing rules, and are accompanied by registration rights agreements.
Corporate and listing developments form another key stream of Titan news. The company announced a 1-for-20 reverse stock split of its common stock, later reported that it had regained compliance with Nasdaq’s minimum bid price requirement, and then disclosed Nasdaq notices related to periodic reporting and audit committee composition. The most consequential news items concern Titan’s Merger and Contribution and Share Exchange Agreement with TalenTec Sdn. Bhd. (formerly KE Sdn. Bhd.) through Black Titan Corporation, and the subsequent completion of this reverse merger, after which TTNP common stock was expected to cease trading on the Nasdaq Capital Market.
For readers researching TTNP, this news archive provides a chronological view of Titan’s strategic alternatives process, key financing decisions, asset divestitures, board changes, and the final steps leading to its combination with TalenTec and the transition of its public listing to Black Titan ordinary shares. Regular review of these historical news items helps contextualize the company’s path and the regulatory filings associated with its corporate transformation.
Titan Pharmaceuticals (NASDAQ: TTNP) announced positive results from studies of its ProNeura®-based implant of TP-2021, a kappa-opioid receptor agonist, in a mouse model for chronic pruritus. The study demonstrated that TP-2021 implants provided sustained itch suppression for 14 days and maintained therapeutic plasma concentrations. This indicates potential for long-term treatment options for chronic itch, with plans for further optimization and human clinical development. Titan is focused on leveraging its ProNeura technology for various chronic conditions.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) filed its annual report on Form 10-K for the fiscal year ending December 31, 2020, reporting a net loss of approximately $7.4 million from continuing operations, down slightly from $7.5 million in 2019. The discontinued operations incurred a net loss of $10.8 million, compared to $9.0 million in the prior year. Cash and cash equivalents stood at $5.4 million at year-end, supplemented by $8.9 million from a January 2021 offering, expected to sustain operations into Q1 2022. The company continues to focus on early-stage product development following its strategic restructuring.
Titan Pharmaceuticals (NASDAQ: TTNP) announced positive results for its kappa opioid agonist peptide, JT-09, showing high potency for the human kappa-opioid receptor. The studies indicated that JT-09 is as effective as difelikefalin in reducing itch in mouse models. With potential therapeutic concentrations deliverable via ProNeura implants for over six months, Titan plans to advance to a non-clinical proof-of-concept study. These developments aim to address chronic pruritus, a challenging condition for effective treatment.
Titan Pharmaceuticals (NASDAQ: TTNP) has announced a $9.7 million registered direct offering of common stock and warrants to accredited institutional investors. The company will sell 2,725,000 shares at $3.55 each, with concurrent warrants to buy an equivalent number of shares. After expenses, net proceeds are expected to be approximately $8.9 million, with the offering closing around January 20, 2021. Maxim Group LLC is the placement agent. The shares are offered under a previously effective shelf registration statement.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced on December 15, 2020, that it has regained compliance with Nasdaq's minimum bid price requirement. This confirmation allows the company's common stock to continue trading on the Nasdaq Capital Market, and the scheduled hearing before the Nasdaq Hearings Panel has been cancelled. Titan is a development-stage company focused on proprietary therapeutics utilizing its ProNeura® long-term drug delivery technology, which aims to improve medical outcomes for chronic conditions.
Titan Pharmaceuticals (NASDAQ: TTNP) has executed a 1-for-30 reverse stock split, effective November 30, 2020, at 5:00 p.m. ET. The decision, approved by shareholders, will reduce the total outstanding shares to approximately 6.6 million. Trading under the new CUSIP number (888314606) on a split-adjusted basis will commence on December 1, 2020. No fractional shares will be issued, with shares rounded up to the next whole number. The reverse split aims to improve stock market perception and maintain compliance with listing requirements.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported its third quarter 2020 financial results, showing revenues of approximately $1.1 million, up from $0.9 million in Q3 2019. The company announced a strategic restructuring, focusing on ProNeura® development and discontinuing U.S. Probuphine implant sales. It raised approximately $8.1 million from direct and public offerings and settled all debt obligations. Despite increased operating expenses of $5.8 million, Titan aims to implement its new strategy post-restructuring. The net loss for the quarter was $4.9 million, or $0.05 per share.
Titan Pharmaceuticals (NASDAQ:TTNP) has completed agreements to settle all debt obligations with Molteni & C and Horizon Credit LLC, and to acquire JT Pharmaceuticals' kappa opioid agonist peptide, JT-09. This acquisition aims to utilize Titan's ProNeura technology for chronic pruritus treatment. The completion of these transactions follows Titan's recent public offering concluded on October 30, 2020. Titan's Executive Chairman, Dr. Marc Rubin, stated that the debt settlement allows the company to fully leverage its intellectual property, enhancing its position for future development.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) has priced an underwritten public offering of 80,000,000 units at $0.10 each, expecting gross proceeds of $8.0 million. Each unit consists of one share of common stock and one warrant, with an exercise price of $0.10. The offering will close around October 30, 2020, and is managed by Maxim Group LLC. The registration statement was declared effective by the SEC on October 28, 2020, and further details will be available in a final prospectus.
Titan Pharmaceuticals (NASDAQ:TTNP) announced an agreement to acquire JT Pharmaceuticals' kappa opioid agonist peptide, JT-09, for treating chronic pruritus. This acquisition aims to utilize Titan's ProNeura® long-term drug delivery technology to enhance treatment efficacy. Subject to financing of at least $8 million and other customary conditions, JT Pharma will receive milestone payments for regulatory achievements and a percentage of net sales. Early non-clinical data suggests promising delivery capabilities for the proposed therapy.